Ambry Genetics and RainDance Technologies Announce Partnership for Diagnostics and Genomics Services
News Mar 17, 2010
A global leader for genetic testing and next generation sequencing services, Ambry Genetics is a CLIA certified and CAP accredited Diagnostic and Genomic Services company providing solutions to both clinical and research clients.
“Ambry Genetics has dedicated its investments in technology for the benefit of the scientific and research community,” said Ardy Arianpour, Director of Business Development. “We are motivated to provide our Diagnostic, Genomic and Research customers with the best solutions for their projects, and the addition of RainDance’s RDT 1000 adds a sequence-enrichment offering while providing an option for customers that are in need of high-throughput targeted sequencing with a high level of coverage, completeness and speed.”
Researchers can utilize the RDT 1000 and Ambry Genetics Next Generation Services to either greatly reduce study time, or to improve study quality by running more samples in the same time within the same experimental budget.
“We’re pleased to partner with Ambry Genetics to provide our microdroplet PCR-based solution in conjunction with Ambry’s genetic testing and next generation sequencing services ” said Chris McNary, Chief Commercial Officer of, RainDance Technologies. “PCR is the gold standard for sequence enrichment and allows for high-resolution analysis of rare genetic variations, a focus area of Ambry Genetics’ customers”. Ambry is currently offering RainDance’s sequence enrichment solution and may add two new applications, Methyl-Seq and Ultra-Deep Resequencing in the second half of 2010, further enhancing their customers’ ability to understand the origins and pathways of complex diseases."
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.